JOHNSON & JOHNSON is 298.0x more valuable than NEKTAR THERAPEUTICS by market capitalization ($573.98 B vs $1.93 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NKTR | JNJ |
|---|---|---|
| Market cap | $1.93 B | $573.98 B |
| US-listed rank | #2118 | #20 |
| Revenue (latest FY) | $55.23M | $94.19B |
| Net income (latest FY) | -$164.00M | $26.80B |
| Net margin | -296.9% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 1,949 | 984 |
JOHNSON & JOHNSON is 298.0x more valuable than NEKTAR THERAPEUTICS by market capitalization ($573.98 B vs $1.93 B).
In their latest fiscal years, NEKTAR THERAPEUTICS reported $55.23M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: NEKTAR THERAPEUTICS and JOHNSON & JOHNSON, or browse the full rankings.